Literature DB >> 23404189

Platelet function profiles in patients with diabetes mellitus.

Fabiana Rollini1, Francesco Franchi, Ana Muñiz-Lozano, Dominick J Angiolillo.   

Abstract

Patients with diabetes mellitus (DM) are at high risk for several cardiovascular disorders such as coronary heart disease, stroke, peripheral arterial disease, and congestive heart failure. DM has reached epidemic proportions and its strong association with coronary artery disease is responsible for increased cardiovascular morbidity and mortality. DM patients are characterized by platelet hyperreactivity, which contribute to the enhanced atherothrombotic risk of these subjects. Several mechanisms are involved in the hyperreactive platelet phenotype characterizing DM patients. Furthermore, a large proportion of DM patients show inadequate response to standard antiplatelet treatments and high rate of adverse recurrent cardiovascular events despite compliance with standard antiplatelet treatment regimens. Therefore, new antiplatelet treatment regimens are warranted in DM patients to reduce their atherothrombotic risk. The present manuscript provides an overview on the current status of knowledge on platelet function profiles in patients with DM and therapeutic considerations.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23404189     DOI: 10.1007/s12265-013-9449-0

Source DB:  PubMed          Journal:  J Cardiovasc Transl Res        ISSN: 1937-5387            Impact factor:   4.132


  174 in total

1.  2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

Authors:  Jeffrey L Anderson; Cynthia D Adams; Elliott M Antman; Charles R Bridges; Robert M Califf; Donald E Casey; William E Chavey; Francis M Fesmire; Judith S Hochman; Thomas N Levin; A Michael Lincoff; Eric D Peterson; Pierre Theroux; Nanette Kass Wenger; R Scott Wright; Sidney C Smith
Journal:  Circulation       Date:  2011-03-28       Impact factor: 29.690

2.  Platelet antioxidant enzymes in insulin-dependent diabetes mellitus.

Authors:  G Seghieri; P Di Simplicio; R Anichini; L Alviggi; A De Bellis; F Bennardini; F Franconi
Journal:  Clin Chim Acta       Date:  2001-07-05       Impact factor: 3.786

3.  Altered cellular Ca2+ and Na+ transport in diabetes mellitus.

Authors:  L Mazzanti; R A Rabini; E Faloia; P Fumelli; E Bertoli; R De Pirro
Journal:  Diabetes       Date:  1990-07       Impact factor: 9.461

4.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.

Authors: 
Journal:  Lancet       Date:  1996-11-16       Impact factor: 79.321

Review 5.  Advanced glycation endproducts--role in pathology of diabetic complications.

Authors:  Nessar Ahmed
Journal:  Diabetes Res Clin Pract       Date:  2005-01       Impact factor: 5.602

6.  P2Y12 receptors play a significant role in the development of platelet microaggregation in patients with diabetes.

Authors:  Hiroyuki Matsuno; Haruhiko Tokuda; Akira Ishisaki; Yuan Zhou; Yasuo Kitajima; Osamu Kozawa
Journal:  J Clin Endocrinol Metab       Date:  2004-10-13       Impact factor: 5.958

Review 7.  Diabetes, vascular complications and antiplatelet therapy: open problems.

Authors:  A M Cerbone; N Macarone-Palmieri; G Saldalamacchia; A Coppola; G Di Minno; A A Rivellese
Journal:  Acta Diabetol       Date:  2008-12-02       Impact factor: 4.280

8.  Insulin-induced expression of prostacyclin receptors on platelets is mediated through ADP-ribosylation of Gi alpha protein.

Authors:  N N Kahn
Journal:  Life Sci       Date:  1998       Impact factor: 5.037

Review 9.  Variability in responsiveness to oral antiplatelet therapy.

Authors:  Dominick J Angiolillo
Journal:  Am J Cardiol       Date:  2009-02-02       Impact factor: 2.778

Review 10.  Effects of hyperglycemia and hyperinsulinemia on the tissue factor pathway of blood coagulation.

Authors:  Guenther Boden; A Koneti Rao
Journal:  Curr Diab Rep       Date:  2007-06       Impact factor: 4.810

View more
  18 in total

1.  Flavin monooxygenase 3, the host hepatic enzyme in the metaorganismal trimethylamine N-oxide-generating pathway, modulates platelet responsiveness and thrombosis risk.

Authors:  W Zhu; J A Buffa; Z Wang; M Warrier; R Schugar; D M Shih; N Gupta; J C Gregory; E Org; X Fu; L Li; J A DiDonato; A J Lusis; J M Brown; S L Hazen
Journal:  J Thromb Haemost       Date:  2018-08-09       Impact factor: 5.824

Review 2.  Targeting Select Cellular Stress Pathways to Prevent Hyperglycemia-Related Complications: Shifting the Paradigm.

Authors:  Arshag D Mooradian
Journal:  Drugs       Date:  2016-07       Impact factor: 9.546

Review 3.  Diabetes and antiplatelet therapy: from bench to bedside.

Authors:  Jose R Rivas Rios; Francesco Franchi; Fabiana Rollini; Dominick J Angiolillo
Journal:  Cardiovasc Diagn Ther       Date:  2018-10

Review 4.  Endothelial Dysfunction and Platelet Hyperactivation in Diabetic Complications Induced by Glycemic Variability.

Authors:  Ye Huang; Long Yue; Jiahuang Qiu; Ming Gao; Sijin Liu; Jingshang Wang
Journal:  Horm Metab Res       Date:  2022-07-14       Impact factor: 2.788

5.  Clopidogrel Resistance in a Murine Model of Diet-Induced Obesity Is Mediated by the Interleukin-1 Receptor and Overcome With DT-678.

Authors:  Yifang Sun; Jessica Venugopal; Chiao Guo; Yanbo Fan; Jianping Li; Yanjun Gong; Y Eugene Chen; Haoming Zhang; Daniel T Eitzman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-04-09       Impact factor: 8.311

6.  Pharmacodynamic effects of EV-077 in patients with diabetes mellitus and coronary artery disease on aspirin or clopidogrel monotherapy: results of an in vitro pilot investigation.

Authors:  Fabiana Rollini; Antonio Tello-Montoliu; Ronakkumar Patel; Andrew Darlington; Ryan E Wilson; Francesco Franchi; Ana Muñiz-Lozano; Bhaloo Desai; Norbert Bender; Kjell S Sakariassen; Dominick J Angiolillo
Journal:  J Thromb Thrombolysis       Date:  2014       Impact factor: 2.300

7.  Loss of the insulin receptor in murine megakaryocytes/platelets causes thrombocytosis and alterations in IGF signalling.

Authors:  Samantha F Moore; Christopher M Williams; Edward Brown; Thomas A Blair; Matthew T Harper; Richard J Coward; Alastair W Poole; Ingeborg Hers
Journal:  Cardiovasc Res       Date:  2015-04-22       Impact factor: 10.787

8.  Effects of Exenatide on Coagulation and Platelet Aggregation in Patients with Type 2 Diabetes.

Authors:  Yaqin Zhang; Ruofei Chen; Yangyang Jia; Mingwei Chen; Zongwen Shuai
Journal:  Drug Des Devel Ther       Date:  2021-07-12       Impact factor: 4.162

9.  Thrombopoietin Contributes to Enhanced Platelet Activation in Patients with Type 1 Diabetes Mellitus.

Authors:  Ornella Bosco; Barbara Vizio; Gabriella Gruden; Martina Schiavello; Bartolomeo Lorenzati; Paolo Cavallo-Perin; Isabella Russo; Giuseppe Montrucchio; Enrico Lupia
Journal:  Int J Mol Sci       Date:  2021-06-29       Impact factor: 5.923

Review 10.  Cardiovascular disease in diabetes, beyond glucose.

Authors:  Robert H Eckel; Karin E Bornfeldt; Ira J Goldberg
Journal:  Cell Metab       Date:  2021-07-21       Impact factor: 31.373

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.